Your browser doesn't support javascript.
loading
Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression.
Anttila, Jani V; Shubin, Mikhail; Cairns, Johannes; Borse, Florian; Guo, Qingli; Mononen, Tommi; Vázquez-García, Ignacio; Pulkkinen, Otto; Mustonen, Ville.
Afiliação
  • Anttila JV; Organismal and Evolutionary Biology Research Programme, University of Helsinki, Helsinki, Finland.
  • Shubin M; Department of Computer Science, University of Helsinki, Helsinki, Finland.
  • Cairns J; Organismal and Evolutionary Biology Research Programme, University of Helsinki, Helsinki, Finland.
  • Borse F; Department of Computer Science, University of Helsinki, Helsinki, Finland.
  • Guo Q; Organismal and Evolutionary Biology Research Programme, University of Helsinki, Helsinki, Finland.
  • Mononen T; Department of Computer Science, University of Helsinki, Helsinki, Finland.
  • Vázquez-García I; Organismal and Evolutionary Biology Research Programme, University of Helsinki, Helsinki, Finland.
  • Pulkkinen O; Department of Computer Science, University of Helsinki, Helsinki, Finland.
  • Mustonen V; Organismal and Evolutionary Biology Research Programme, University of Helsinki, Helsinki, Finland.
PLoS Comput Biol ; 15(11): e1007493, 2019 11.
Article em En | MEDLINE | ID: mdl-31738747
ABSTRACT
A tumour grows when the total division (birth) rate of its cells exceeds their total mortality (death) rate. The capability for uncontrolled growth within the host tissue is acquired via the accumulation of driver mutations which enable the tumour to progress through various hallmarks of cancer. We present a mathematical model of the penultimate stage in such a progression. We assume the tumour has reached the limit of its present growth potential due to cell competition that either results in total birth rate reduction or death rate increase. The tumour can then progress to the final stage by either seeding a metastasis or acquiring a driver mutation. We influence the ensuing evolutionary dynamics by cytotoxic (increasing death rate) or cytostatic (decreasing birth rate) therapy while keeping the effect of the therapy on net growth reduction constant. Comparing the treatments head to head we derive conditions for choosing optimal therapy. We quantify how the choice and the related gain of optimal therapy depends on driver mutation, metastasis, intrinsic cell birth and death rates, and the details of cell competition. We show that detailed understanding of the cell population dynamics could be exploited in choosing the right mode of treatment with substantial therapy gains.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Citotoxinas / Citostáticos / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Citotoxinas / Citostáticos / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article